Insider buying last 90 days
No open-market insider purchases were filed for COGT in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Cogent Biosciences reported third-quarter 2026 financial results this week, highlighting preparations for the anticipated launch of bezuclastinib in GIST and other systemic mastocytosis indications, alongside a wider quarterly net loss of $111.4 million, up from $80.9 million a year prior, driven by increased research and development and general and administrative expenses. The company also disclosed $791 million in cash and securities. Separately, HC Wainwright & Co. maintained its Buy rating and raised its price target to $56 from $55, and a DCF-based analysis suggested the stock could be significantly undervalued relative to estimated future cash flow value.
COGT closed at $33.54, up 6% on the day, with the stock sitting between its 50-day average of $31.80 and 200-day average of $35.47. The GekkoIndex reads 54.2, placing the stock in the Neutral zone. Price sits 12.1% below Gekko Fair Value of $38.14. One-month returns stand at 8.2%, while three-month returns are -13.3%, and the stock's 52-week range spans $13.93 to $43.73.
The next earnings date falls on 16 February 2027, 93 days away, outside a typical 20-trading-day holding window. No insider, Congress, or unusual options activity in the respective windows is noted in current signals. Analyst sentiment skews heavily positive, with 8 of 9 firms rating the stock Buy and a consensus target of $55.82, implying 66.4% consensus upside. Seasonality data shows the next 20 trading days have averaged a 31.8% return over 5 years, rising in 3 of those years, a pattern worth noting given the stock's typical 20-day move of 11.5%.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Cogent Biosciences scores 3 supportive, 0 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive0 mixed2 headwinds
Below 50 and 200-day
Close $28.56 is below the 50-day ($31.39) and 200-day ($35.30) averages, and the 50-day is below the 200-day.
See the chart63.4, Accumulation
Reading 63.4 is in the Accumulation zone.
See the GekkoIndex24.0% below
Price is 24% below Gekko Fair Value (more than 5% below).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 93 days
Next report Feb 16, 2027, 93 days away — outside a typical 20-trading-day hold.
See earnings−12.5% on average
From this point in the calendar, the next 20 trading days averaged −12.5% over 5 years, rising in 1 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Cogent Biosciences closed at $28.56 on Nov 13, 2026, −19.0% over the past year, inside a 52-week range of $27.74 to $43.73.
Use the left and right arrow keys to read daily values.
Put COGT on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Cogent Biosciences develops medicines aimed at diseases caused by specific genetic mutations. Its lead candidate is a selective tyrosine kinase inhibitor designed to target the KIT D816V mutation linked to systemic mastocytosis, as well as other KIT exon 17 mutations found in patients with advanced gastrointestinal stromal tumors. This mutation-targeted drug candidate is the focus most associated with the company.
The company works under a licensing arrangement with Plexxikon Inc. that gives it the ability to research, develop, and commercialize this compound, known as bezuclastinib. Cogent Biosciences was formerly named Unum Therapeutics Inc. before it took on its present name in October 2020.
Founded in 2014, Cogent Biosciences is based in Cambridge, Massachusetts. Its shares trade on the NASDAQ under the ticker COGT.
Cogent Biosciences’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 63.4, in the Accumulation zone, up 5 points over five sessions.
Up 5 points over five sessions, from the Neutral zone.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 38 | +1.5% | +6.9% | ||
| Accumulation (current zone) | 203 | +2.9% | +6.1% | ||
| Neutral | 395 | +1.5% | +10.1% | ||
| Distribution | 59 | +4.7% | +8.0% | ||
| Selling | 7 | Too few readings yet | |||
Average COGT share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
Cogent Biosciences trades 24.0% below Gekko Fair Value of $37.57, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Cogent Biosciences shares are worth, recalculated every trading day.
$37.57
Gekko Fair Value, Nov 14, 2026
24.0% Undervalued
At the end of Aug 2026 the price was 30.4% below the estimate.
No open-market insider purchases were filed for Cogent Biosciences, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for COGT in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in COGT were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
0of the funds Gekko tracks hold COGT.
Cogent Biosciences reports on Feb 16, 2027 (93 days away), and beat the EPS estimate in 4 of its last 8 reports.
Feb 16, 2027
93 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 10, 2026 | −$0.52 est −$0.55 | — est $1K | −8.7% |
| May 5, 2026 | −$0.53 est −$0.53 | — est $500 | −2.3% |
| Feb 17, 2026 | −$0.55 est −$0.51 | — est $1.68M | +5.0% |
| Nov 7, 2025 | −$0.50 est −$0.54 | — | +120.5% |
| Aug 5, 2025 | −$0.53 est −$0.55 | — | −9.0% |
| May 6, 2025 | −$0.52 est −$0.56 | — | −15.3% |
| Feb 25, 2025 | −$0.61 est −$0.59 | — | −10.1% |
| Nov 12, 2024 | −$0.64 est −$0.55 | — | 0.0% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Cogent Biosciences is $55.82, +95.4% from the last close, from 8 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 8 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 12 | J.P. Morgan | $61 | +113.6% |
| Nov 9 | H.C. Wainwright | $56 | +96.1% |
| Nov 6 | Wedbush | $55 | +92.6% |
| Nov 6 | Stifel Nicolaus | $45 | +57.6% |
| Oct 27 | Stifel Nicolaus | $45 | +57.6% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Cogent Biosciences averaged −12.5% across the last 5 years, rising in 1 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −5.3% | 1 of 5 |
| Next 10 trading days | −2.2% | 2 of 5 |
| Next 15 trading days | +1.6% | 3 of 5 |
| Next 20 trading days | −12.5% | 1 of 5 |
| Next 30 trading days | −12.3% | 1 of 5 |
For scale, COGT’s typical 20-trading-day move in either direction is about 11.5%.
Cogent Biosciences’s market cap is $4.97B and revenue of $0 over the last twelve months.
Coverage of Cogent Biosciences this week reads neutral: 2 positive, 0 neutral and 2 negative headlines.
Cogent Biosciences’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 19.9% below |
| GILDGilead Sciences | Neutral | 11.7% above |
| MRNAModerna | Neutral | 21.1% above |
| NTRANatera | Accumulation | 18.6% below |
| IQVIQVIA | Accumulation | 5.0% above |
| UTHRUnited Therapeutics | Neutral | 11.2% below |
A peer links to its own page where one exists.
Cogent Biosciences’s market cap is $4.97B at the Nov 13, 2026 close of $28.56, with 174.0M shares outstanding.
The consensus analyst 12-month price target for Cogent Biosciences is $55.82, +95.4% from the last close. Of the 8 firms that rated the stock in the last 90 days, 8 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Cogent Biosciences is undervalued: the Nov 13, 2026 close of $28.56 is 24.0% below Gekko Fair Value of $37.57. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Cogent Biosciences is expected to report on Feb 16, 2027 (93 days away). Analysts expect earnings of −$0.61 per share on revenue of $5.44M. Cogent Biosciences beat the earnings estimate in 4 of its last 8 reports, moving 21.4% on average across the report.
Cogent Biosciences’s 52-week high is $43.73 and its 52-week low is $27.74; it closed at $28.56 on Nov 13, 2026, −19.0% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and earnings risk) and 2 as headwinds (trend and seasonality). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.